ISS National Lab experiment pushes 3D bioprinted liver tissue research into space

Researchers from the Wake Forest Institute for Regenerative Medicine are taking a bold step in advancing regenerative medicine by sending 3D bioprinted liver tissue constructs to the International Space Station. The experiment, sponsored by the International Space Station National Laboratory (ISS National Lab), is scheduled to launch aboard SpaceX’s 33rd Commercial Resupply Services mission, under contract with NASA. The goal is to better understand how microgravity influences the maturation of engineered tissue, particularly with vascular channels that mimic the intricate blood vessels of the human liver.

Why is microgravity considered a breakthrough environment for 3D bioprinted liver tissue research?

Bioprinting is one of the most closely watched frontiers in medical science, enabling scientists to fabricate three-dimensional structures using living human cells. These living constructs can serve multiple purposes, from modeling disease pathways to repairing tissue damaged by trauma, chronic illness, or aging. The liver has long been a focal point in this field because of its vital role in metabolism, detoxification, and overall human health. However, engineering large, thick tissues has remained challenging on Earth due to limited vascularization. Without adequate networks of blood vessels, tissues cannot efficiently deliver oxygen and nutrients or remove waste, which leads to loss of viability over time.

This is where microgravity provides an unusual advantage. Past research has shown that cells behave differently in space: they distribute, adhere, and grow in unique ways that may better support the creation of robust tissue structures. By eliminating Earth’s gravitational pull, scientists expect to observe whether liver and vascular cells can align more naturally into functional tissues. According to the ISS National Lab, these insights could accelerate breakthroughs not only in regenerative medicine but also in long-term space exploration, where the ability to repair or replace human tissue could prove essential.

How is Wake Forest Institute for Regenerative Medicine using the ISS to advance bioprinted liver tissue research?

The Wake Forest Institute for Regenerative Medicine (WFIRM), based in North Carolina, has long been recognized as a leader in tissue engineering and organ regeneration. The institute previously achieved success in engineering liver tissue constructs with vascular channels that remained functional for up to 30 days in laboratory conditions on Earth. Building on this progress, the team is now using Redwire Space’s Multi-Use Variable-Gravity Platform (MVP) aboard the space station to test whether microgravity enhances tissue maturation and stability.

Professor James Yoo, who is leading the investigation at WFIRM, has emphasized that this work is not only about understanding microgravity’s effects but also about solving one of regenerative medicine’s most fundamental challenges—keeping bioprinted tissues viable over the long term. Yoo explained that WFIRM’s team has created gel-like scaffolds embedded with vascular channels, designed to replicate natural blood vessels. If microgravity allows these channels to function more effectively, the path toward bioengineered organs suitable for transplantation could become significantly shorter.

What role did NASA’s Vascular Tissue Challenge play in accelerating bioprinted organ and vascular tissue innovations?

The project stems from NASA’s Vascular Tissue Challenge, a competition designed to inspire innovation in tissue engineering for both space and terrestrial healthcare applications. WFIRM entered two teams—Team Winston and Team WFIRM—both of which successfully created 3D-printed tissue constructs and demonstrated their viability on Earth. Their success earned them combined prize money of $400,000, which helped advance their research toward space-based trials.

Team Winston, in particular, has been given the opportunity to send their constructs to the ISS. The team will closely analyze whether vascular cells within the printed liver constructs correctly form linings in vessel walls, a critical milestone for functional tissue. This step marks the first time their innovation will be tested in space, and it builds on years of groundwork by NASA and the regenerative medicine community.

How are NASA, Methuselah Foundation, and ISS National Lab partnerships supporting regenerative medicine breakthroughs in space?

Behind this research effort is a coalition of organizations aligned by a shared mission to expand the possibilities of human health and longevity. The Methuselah Foundation, through its New Organ Alliance, organized the Vascular Tissue Challenge for NASA. David Gobel, the foundation’s co-founder and chief executive officer, noted that advancing regenerative medicine is central to both improving quality of life on Earth and preparing humans for extended stays in space. By supporting projects like WFIRM’s, Methuselah Foundation underscores its broader commitment to human longevity and medical innovation.

In addition, the ISS National Lab continues to serve as a platform for pioneering research that bridges terrestrial science with space-based experimentation. More than 20 ISS National Lab-sponsored payloads are expected to launch on the upcoming SpaceX resupply mission, further illustrating the growing importance of the orbiting laboratory as a hub for biomanufacturing and cutting-edge R&D.

How does the ISS liver tissue experiment connect to the global regenerative medicine market and long-term healthcare innovation?

The field of regenerative medicine has been steadily growing over the past two decades, with global investment increasing significantly in areas such as stem cell therapy, 3D bioprinting, and gene editing. According to data from the Alliance for Regenerative Medicine, the sector attracted more than $23 billion in financing between 2020 and 2023, underscoring the appetite for breakthroughs that could transform patient care. Major pharmaceutical companies and academic research centers alike are pouring resources into regenerative therapies, with liver disease representing one of the most urgent targets due to its prevalence and limited treatment options.

Bioprinting is increasingly viewed as a realistic pathway to addressing organ shortages. In the United States alone, over 100,000 people are currently on transplant waiting lists, with livers among the most in-demand organs. By developing the capability to grow artificial tissues that can replace or repair damaged livers, institutions like WFIRM are tackling a challenge that affects millions worldwide. Testing these technologies in microgravity adds an important dimension, as it may provide lessons that accelerate progress back on Earth.

Why is biotechnology becoming a central driver of the space economy and how does bioprinting fit into this trend?

The intersection of space and biotechnology is gaining attention as a critical growth area in the so-called “space economy.” Beyond traditional aerospace companies, biotech and pharmaceutical firms are beginning to recognize that microgravity can unlock new discoveries in areas such as drug development, protein crystallization, and tissue engineering. For NASA, these collaborations are part of a long-term strategy to expand the benefits of space exploration to life on Earth, while for private companies and research institutions, space-based experiments offer unique competitive advantages.

Investors are also watching closely. Although companies like WFIRM are not publicly traded, broader market sentiment toward biotech innovation has been favorable, particularly for firms that demonstrate leadership in areas with high clinical and commercial potential. Institutional investors increasingly factor in regenerative medicine advancements when evaluating long-term healthcare trends, which could influence capital flows into the sector.

What are the long-term implications of bioprinting human organs in space for healthcare, transplantation, and deep space missions?

If WFIRM’s investigation demonstrates that microgravity improves tissue maturation and vascularization, it could mark a turning point in the timeline for functional bioprinted organs. Analysts suggest that while full organ transplantation from bioprinted constructs may still be a decade or more away, incremental progress in tissue viability could unlock new therapies sooner. For example, engineered tissues may be used for disease modeling, drug testing, or partial transplants that supplement failing organs.

In the long run, the ability to biomanufacture tissue in space could also support future missions to Mars and beyond. Astronauts on extended missions face risks of radiation damage, muscle loss, and organ stress. Having the ability to repair tissue or even replace organs in space could dramatically improve the feasibility of long-duration space travel. This aligns with NASA’s broader Artemis program and its vision for a sustainable human presence beyond Earth.

Why are biotech investors, analysts, and the healthcare sector closely watching the ISS bioprinting liver tissue experiment?

The upcoming launch from Cape Canaveral Space Force Station, scheduled no earlier than August 24, 2025, will be watched closely not just by space enthusiasts but by the global biotech community. With over 20 ISS National Lab-sponsored experiments set to fly, the mission underscores the expanding role of the space station as a crucible for innovation. For WFIRM, Team Winston, and their partners, the mission represents both a scientific opportunity and a symbolic milestone in humanity’s pursuit of medical self-sufficiency.

If successful, this experiment could strengthen investor and institutional confidence in regenerative medicine research and encourage greater collaboration between aerospace and biotech industries. As the line between Earth-based healthcare challenges and space-based solutions continues to blur, the implications of this work could resonate across both sectors for years to come.